Let’s imagine an AML for which the molecular diagnosis finds an NPM1 mutation, whose prognosis is modified by the presence of competing mutations of FLT3, DNMT3, NRAS, IDH or PTPN11 for example. This evidence concerns the gene IDH2 and acute myeloid leukemia.